ETV7

ETV7 is an ETS-family transcription factor that functions as both a transcriptional repressor and activator to regulate cell differentiation, proliferation, immune signaling, and drug resistance. In the nucleus, ETV7 binds ETS consensus motifs (GGAA core) via its ETS domain and uses its PNT/SAM domain for homo- and hetero-oligomerization and transcriptional repression; it directly represses SERPINE1, DNAJC15, and TNFRSF1A to modulate metastasis, chemoresistance, and NF-κB signaling, while activating IFIT3 and CXCL1 to promote tumor proliferation and immune evasion (PMID:26335051, PMID:30025229, PMID:37041130, PMID:38200280, PMID:41917269). In the cytoplasm, ETV7 interacts with mTOR through dual PNT–FRB and ETS–LBE interfaces to assemble mTORC3, a rapamycin-insensitive mTOR complex lacking Raptor and Rictor that confers drug resistance (PMID:30258985, PMID:39337528). ETV7 also drives CD8+ T cell terminal exhaustion by binding memory and exhaustion gene loci, and its depletion enhances antitumor T cell and CAR-T cell efficacy in vivo (PMID:39805956).

1. 2000 Medium

   Establishing ETV7 as a nuclear ETS-family transcriptional repressor resolved the basic molecular identity of this gene, showing it binds the canonical GGAA motif and self-associates via its PNT domain.

   Evidence DNA binding assays, co-immunoprecipitation in transfected HeLa cells, reporter gene assays with isoform and domain deletion mutants

   PMID:10828014 PMID:11108721

   Open questions at the time

   • No genome-wide binding profile to define the full target repertoire
   • Repression mechanism (corepressor recruitment, chromatin modification) not identified
   • Reporter-based; endogenous gene repression not shown
2. 2005 High

   Demonstrating that ETV7 cooperates with Myc in lymphomagenesis and causes myeloproliferative disease upon forced expression established ETV7 as a bona fide oncogene that promotes proliferation while blocking myeloid differentiation.

   Evidence Eμ-Myc transgenic mouse crosses, bone marrow transplantation, retroviral overexpression, differentiation assays in U937/HL60 cells

   PMID:15743832 PMID:16234363

   Open questions at the time

   • Transcriptional targets mediating oncogenicity not identified
   • Relationship to p53 pathway inactivation is correlative
   • Human relevance of mouse phenotypes not confirmed
3. 2012 Medium

   Showing that ETV7's SAM domain inhibits ETS1, ETS2, and ETV6 transcriptional activities revealed a cross-regulatory mechanism among ETS factors, explaining how ETV7 can antagonize the tumor-suppressive function of ETV6.

   Evidence Transcriptional reporter assays with SAM domain constructs, cross-species comparison with Drosophila Mae

   PMID:22615925

   Open questions at the time

   • Direct physical interaction with ETS1/ETS2 not demonstrated by co-IP
   • Endogenous relevance in mammalian cells not shown
   • Stoichiometric relationship between ETV7 and other ETS factors unknown
4. 2015 High

   Identification of SERPINE1 as a direct transcriptional target repressed by ETV7 provided the first ChIP-validated target gene linking ETV7 to a specific cellular phenotype — suppression of metastasis.

   Evidence ChIP assay and luciferase reporter assay for direct promoter binding, migration/invasion assays, in vivo metastasis model in nasopharyngeal carcinoma

   PMID:26335051

   Open questions at the time

   • Genome-wide ChIP-seq not performed to define all direct targets
   • Whether ETV7–SERPINE1 axis operates in other cancer types untested
5. 2018 High

   Discovery that ETV7 assembles a rapamycin-insensitive third mTOR complex (mTORC3) in the cytoplasm, independent of its transcriptional activity, fundamentally expanded ETV7's functional repertoire beyond transcription and explained a mechanism of mTOR inhibitor resistance.

   Evidence Co-immunoprecipitation, size-exclusion chromatography, kinase activity assays, rapamycin sensitivity assays, rhabdomyosarcoma mouse model

   PMID:30258985

   Open questions at the time

   • Structural basis of mTORC3 assembly unknown
   • Full subunit composition of mTORC3 not defined
   • Endogenous complex stoichiometry not established
6. 2018 Medium

   Identification of DNAJC15 as a second direct transcriptional target of ETV7, whose repression mediates doxorubicin resistance via increased drug efflux, linked ETV7's repressor activity to chemoresistance.

   Evidence ChIP, siRNA knockdown, drug efflux assays, DNAJC15 overexpression rescue in breast cancer cells

   PMID:30025229

   Open questions at the time

   • Relative contribution of DNA methylation vs. ETV7 binding to DNAJC15 repression not delineated
   • Generalizability beyond breast cancer not tested
7. 2023 High

   Demonstrating that ETV7 binds TNFRSF1A intron I and competes with STAT3 for binding, repressing TNFR1 and dampening NF-κB signaling, revealed a mechanism by which ETV7 modulates inflammatory signaling through direct chromatin competition.

   Evidence ChIP assay, NF-κB signaling assays, competitive binding experiments with STAT3

   PMID:37041130

   Open questions at the time

   • Whether STAT3 displacement is direct or allosteric is unresolved
   • Identity of recruited chromatin remodelers not specified
8. 2024 High

   Mapping the dual ETV7–mTOR interaction interfaces (PNT–FRB and ETS–LBE) and showing that FRB domain overexpression restores rapamycin sensitivity in vivo provided a structural rationale and a potential therapeutic strategy to disrupt mTORC3.

   Evidence Domain mapping by co-immunoprecipitation with truncation/deletion mutants, in vivo competition assay with FRB overexpression

   PMID:39337528

   Open questions at the time

   • No high-resolution structural data for the ETV7–mTOR interfaces
   • Whether pharmacological small molecules can mimic FRB competition unknown
9. 2024 Medium

   Establishing that ETV7 acts as a transcriptional activator of IFIT3 in colorectal cancer demonstrated that ETV7 is not exclusively a repressor, and that an ETV7–IFIT3 axis drives proliferation.

   Evidence Luciferase reporter assay, RT-qPCR, siRNA knockdown and rescue in colorectal cancer cells

   PMID:38200280

   Open questions at the time

   • Mechanism switching ETV7 from repressor to activator at specific loci not explained
   • Single cancer type studied
10. 2025 High

    Revealing that ETV7 drives CD8+ T cell terminal exhaustion by binding memory and exhaustion gene loci established ETV7 as a key immune checkpoint transcription factor, with its depletion enhancing antitumor T cell and CAR-T efficacy.

    Evidence scRNA-seq, scATAC-seq, ETV7 overexpression and depletion, in vivo tumor models, direct chromatin binding analysis

    PMID:39805956

    Open questions at the time

    • Cofactors mediating ETV7's chromatin remodeling at exhaustion loci unknown
    • Whether ETV7's T cell role is mTORC3-dependent not addressed
    • Clinical translation to CAR-T engineering not validated in patients
11. 2026 Medium

    Showing that ETV7 transcriptionally activates CXCL1, promoting neutrophil recruitment and NET formation in the tumor microenvironment, connected ETV7 to immune cell remodeling and 5-FU resistance in colorectal cancer.

    Evidence ChIP, luciferase reporter assay, CXCL1 neutralization, NETs inhibition, in vivo and in vitro functional assays

    PMID:41917269

    Open questions at the time

    • Whether ETV7 directly regulates other chemokines is unexplored
    • Mechanism of NET-mediated chemoresistance downstream of CXCL1 not fully dissected
    • Single lab study

• Key unresolved questions include the structural basis of mTORC3, the cofactors and chromatin mechanisms that determine whether ETV7 acts as a repressor or activator at specific loci, and whether ETV7's cytoplasmic (mTORC3) and nuclear (transcriptional) functions are coordinated or independent.
• No cryo-EM or crystal structure of mTORC3 or ETV7 in complex with mTOR
• Genome-wide ChIP-seq in primary human tissues not performed
• Functional interplay between mTORC3 assembly and transcriptional programs unresolved